Skip to content

Study · Randomized controlled trial · n = 1,085 · 2012

7 results

Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.

Krege JH, Wan X

Bone22 Oct 2011Cited by 31 (Europe PMC)

PMID22036910 (opens in a new tab)DOI10.1016/j.bone.2011.10.018 (opens in a new tab)PepBankPUB-22036910
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide did not significantly reduce nonvert-6 fractures versus placebo.

    In plain wordsTeriparatide did not significantly reduce nonvert-6 fractures compared with placebo in women with osteoporosis.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeNonvert-6 fractures
    Study

    n = 1,085

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · self-injection · Median 19 monthsAs given in this study (human).

    Measurements

    Relative risk
    0.54 ratio
    nonvert-6 fractures

    Source sentences

    Summary
    For teriparatide versus placebo, the point estimates for the RR of nonvert-6 (RR 0.54, P=0.06; fragility RR 0.32, P=0.014), FDA (RR 0.60, P=0.15; fragility RR 0.38, P=0.05), and major (RR 0.52, P=0.02; fragility RR 0.38, P=0.02) nonvertebral fracture endpoints were smaller than for the all nonverteb…
    1 context sentence
    Summary · context
    The Fracture Prevention Trial was a double-blind trial of postmenopausal women with osteoporosis and vertebral fractures randomly assigned to teriparatide (N=541) or placebo (N=544) administered by daily self-injection for a median of 19 months and a median follow-up of 21 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide reduced fragility nonvert-6 fractures versus placebo.

    In plain wordsTeriparatide reduced fragility nonvert-6 fractures compared with placebo in women with osteoporosis.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFragility nonvert-6 fractures
    Study

    n = 1,085

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · self-injection · Median 19 monthsAs given in this study (human).

    Measurements

    Relative risk
    0.32 ratio
    fragility nonvert-6 fractures

    Source sentences

    Summary
    For teriparatide versus placebo, the point estimates for the RR of nonvert-6 (RR 0.54, P=0.06; fragility RR 0.32, P=0.014), FDA (RR 0.60, P=0.15; fragility RR 0.38, P=0.05), and major (RR 0.52, P=0.02; fragility RR 0.38, P=0.02) nonvertebral fracture endpoints were smaller than for the all nonverteb…
    1 context sentence
    Summary · context
    The Fracture Prevention Trial was a double-blind trial of postmenopausal women with osteoporosis and vertebral fractures randomly assigned to teriparatide (N=541) or placebo (N=544) administered by daily self-injection for a median of 19 months and a median follow-up of 21 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide did not significantly reduce FDA-set nonvertebral fractures versus placebo.

    In plain wordsTeriparatide did not significantly reduce FDA-set nonvertebral fractures compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFDA-set nonvertebral fractures
    Study

    n = 1,085

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · self-injection · Median 19 monthsAs given in this study (human).

    Measurements

    Relative risk
    0.6 ratio
    FDA-set fractures

    Source sentences

    Summary
    For teriparatide versus placebo, the point estimates for the RR of nonvert-6 (RR 0.54, P=0.06; fragility RR 0.32, P=0.014), FDA (RR 0.60, P=0.15; fragility RR 0.38, P=0.05), and major (RR 0.52, P=0.02; fragility RR 0.38, P=0.02) nonvertebral fracture endpoints were smaller than for the all nonverteb…
    1 context sentence
    Summary · context
    The Fracture Prevention Trial was a double-blind trial of postmenopausal women with osteoporosis and vertebral fractures randomly assigned to teriparatide (N=541) or placebo (N=544) administered by daily self-injection for a median of 19 months and a median follow-up of 21 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide was associated with fewer FDA-set fragility nonvertebral fractures than placebo (RR 0.38, P=0.05).

    In plain wordsFewer FDA-set fragility fractures occurred with teriparatide than with placebo (relative risk 0.38, P=0.05).

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFDA-set fragility nonvertebral fractures
    Study

    n = 1,085

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · self-injection · Median 19 monthsAs given in this study (human).

    Measurements

    Relative risk
    0.38 ratio
    FDA-set fragility fractures

    Source sentences

    Summary
    For teriparatide versus placebo, the point estimates for the RR of nonvert-6 (RR 0.54, P=0.06; fragility RR 0.32, P=0.014), FDA (RR 0.60, P=0.15; fragility RR 0.38, P=0.05), and major (RR 0.52, P=0.02; fragility RR 0.38, P=0.02) nonvertebral fracture endpoints were smaller than for the all nonverteb…
    1 context sentence
    Summary · context
    The Fracture Prevention Trial was a double-blind trial of postmenopausal women with osteoporosis and vertebral fractures randomly assigned to teriparatide (N=541) or placebo (N=544) administered by daily self-injection for a median of 19 months and a median follow-up of 21 months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide reduced major nonvertebral fractures versus placebo.

    In plain wordsTeriparatide reduced major nonvertebral fractures compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseMajor nonvertebral fractures
    Study

    n = 1,085

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · self-injection · Median 19 monthsAs given in this study (human).

    Measurements

    Relative risk
    0.52 ratio
    major fractures

    Source sentences

    Summary
    For teriparatide versus placebo, the point estimates for the RR of nonvert-6 (RR 0.54, P=0.06; fragility RR 0.32, P=0.014), FDA (RR 0.60, P=0.15; fragility RR 0.38, P=0.05), and major (RR 0.52, P=0.02; fragility RR 0.38, P=0.02) nonvertebral fracture endpoints were smaller than for the all nonverteb…
    1 context sentence
    Summary · context
    The Fracture Prevention Trial was a double-blind trial of postmenopausal women with osteoporosis and vertebral fractures randomly assigned to teriparatide (N=541) or placebo (N=544) administered by daily self-injection for a median of 19 months and a median follow-up of 21 months.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide reduced major fragility nonvertebral fractures versus placebo.

    In plain wordsTeriparatide reduced major fragility nonvertebral fractures compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseMajor fragility nonvertebral fractures
    Study

    n = 1,085

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · self-injection · Median 19 monthsAs given in this study (human).

    Measurements

    Relative risk
    0.38 ratio
    major fragility fractures

    Source sentences

    Summary
    For teriparatide versus placebo, the point estimates for the RR of nonvert-6 (RR 0.54, P=0.06; fragility RR 0.32, P=0.014), FDA (RR 0.60, P=0.15; fragility RR 0.38, P=0.05), and major (RR 0.52, P=0.02; fragility RR 0.38, P=0.02) nonvertebral fracture endpoints were smaller than for the all nonverteb…
    1 context sentence
    Summary · context
    The Fracture Prevention Trial was a double-blind trial of postmenopausal women with osteoporosis and vertebral fractures randomly assigned to teriparatide (N=541) or placebo (N=544) administered by daily self-injection for a median of 19 months and a median follow-up of 21 months.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide did not significantly reduce traumatic nonvertebral fractures versus placebo.

    In plain wordsTeriparatide did not significantly reduce traumatic nonvertebral fractures compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTraumatic nonvertebral fractures
    Study

    n = 1,085

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · self-injection · Median 19 monthsAs given in this study (human).

    Source sentences

    Summary
    Lower RRs were observed when the outcomes were limited to fragility fractures, and significant reductions in traumatic nonvertebral fractures were not observed.
    1 context sentence
    Summary · context
    The Fracture Prevention Trial was a double-blind trial of postmenopausal women with osteoporosis and vertebral fractures randomly assigned to teriparatide (N=541) or placebo (N=544) administered by daily self-injection for a median of 19 months and a median follow-up of 21 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.